Precision in Anticoagulant Therapy: The Role of Genotyping in Warfarin Treatment

Warfarin is one of the most commonly prescribed oral anticoagulants worldwide. It is highly effective in preventing and treating thromboembolic disorders, but achieving the right dose is challenging — too low a dose may leave patients at risk of clot formation, while too high a dose can cause serious bleeding.
One of the key reasons for this variability lies in our genes.

How Warfarin Works

Warfarin acts by inhibiting the enzyme vitamin K epoxide reductase (VKORC1), which is essential for recycling vitamin K in the liver. Vitamin K, in its active reduced form, enables the activation of several vitamin K–dependent clotting factors (II, VII, IX, and X). By blocking VKORC1, Warfarin lowers the availability of active vitamin K, thereby reducing the synthesis of these clotting factors and producing an anticoagulant effect. Because the relationship between dose and therapeutic effect is narrow, even modest differences in metabolism or sensitivity can significantly impact patient safety.

Key Genetic Determinants

CYP2C9 Gene Variants

Warfarin is mainly metabolized in the liver by the enzyme CYP2C9, which converts the more active S-enantiomer of Warfarin into inactive metabolites.
Two common polymorphisms — CYP2C9*2 (rs1799853, c.430C>T) and CYP2C9*3 (rs1057910, c.1075A>C) — result in amino acid substitutions that reduce the enzyme’s metabolic capacity.

Reduced CYP2C9 activity leads to slower Warfarin clearance, prolonged half-life, and accumulation of the drug. Patients with these alleles reach a therapeutic INR more slowly and are at increased risk of over-anticoagulation if standard doses are used.

VKORC1 G1639A Polymorphism

The VKORC1 gene encodes the Warfarin target enzyme.
A single nucleotide polymorphism in its promoter region — G1639A (rs9923231) — affects gene expression:

• G allele → higher VKORC1 expression → lower Warfarin sensitivity
• A allele → reduced VKORC1 expression → higher sensitivity to Warfarin

Individuals with AA genotype often require 30–50 % lower doses than GG carriers. This variant is especially frequent in East-Asian populations, where average Warfarin dose requirements are notably lower than in European cohorts.

Benefits of Genotyping Before Warfarin Therapy

Identifying a patient’s CYP2C9 and VKORC1 genotypes allows clinicians to:

• Estimate the optimal initial Warfarin dose,
• Reach target INR faster with fewer adjustments,
• Reduce the risk of bleeding or subtherapeutic anticoagulation,
• Increase patient safety and confidence in treatment.

Pharmacogenetic guidelines, including those from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the FDA, now recommend considering these genetic markers before initiating Warfarin therapy.

Radovan Haluza